How It Works

 

Clinically proven in multiple trials to maintain lasting site health

embrace® ACTIVE SITE CARE

The only 510(k) cleared patch that uses mechano-modulation via tension-offloading technology to effectively manage lipohypertrophy (LH) and scarring.

Our patented mechanism of action (MOA) is proven to control inflammation, excessive fibrosis and collagen deposition, thus minimizing scar tissue and LH formation that:

  • damages healthy sites
  • limits site access for insulin delivery
  • impairs consistent insulin uptake

 

Shop embrace®

Unique Dual Action Technology

Our patented tension-offloading technology primes the healing environment, regulates fibroblasts, and prevents over production of collagen that is the root cause of scar & LH formation

 

 

 

Contracts
When Applied, the embrace®patch shrinks and delivers an active, compressive force directly to the treatment site, off-loading skin tension
Compresses
embrace's continuous compression penetrates deep into the subcutaneous tissue to:
  • Minimize the inflammatory response from micro-injuries
  • Regulate fibroblast production and collagen deposits to prevent the formation of scar tissue
  • Repair exhausted sites by remodeling damaged tissue
Compression Control

Compression controls the healing environment for deep subcutaneous healing to repair exhausted sites.

Proven Effective Below the Skin

embrace patch is the only site management tool proven in robust clinical trial 

 

Active compression continuously during 15-day wear maximizes results at each rotation site

Site Exhaustion

Daily microtraumas trigger the growth of LH and scar tissue.

Active Phase
Day 1-9: Tension-offloading w/ embrace

embrace shrinks to compress the site, reducing the body's inflammatory response.

Clinically Verified
Day 10-15: Healthy skin

Compression controls the healing environment, allowing healthy tissue to form in the place of scars and LH.

One box equals
One month's supply

Amplify the Benefits of
Site Rotation

Your site health plays a critical role in your diabetes management plan. The embrace patch can be used in combination with site rotation patterns to minimize the damage from insertion of CGMs, pump sets, and insulin injections.

Compatible & Convenient
Works with Pumps, MDIs & CGMs
Available in 3 sizes (6cm, 12cm, 16cm)

 

Select the rotation guide below that aligns with your personal diabetes management routine

 

Download

stack of papers Tips for Patients Using CGMs

Experts agree with the following steps*:

  • Choose a part of the body
  • Divide into 4 areas
  • Use one area every 7-10 days depending on your CGM
  • Always use a new site
  • Avoid using a single site more than once every 4 weeks
  • Follow your health care professional's recommendations for site rotation

Use for diabetes-related injection-induced scarring

Scarring from on-going use of wearables can significantly impact glycemic control

  • GREATER glycemic variability - up to 7 times higher*
  • INCREASED use of insulin - up to 35% more†
  • HIGHER A1c level - up to 0.55 higher*
diagram of device with parts labeled

STEP 1: Apply

Holding embrace® on its outer edges, use the Peel Tabs to peel off the clear protective liner that covers the adhesive patch.

DO NOT touch the adhesive patch with your fingers.

Gently bow the Applicator with both hands to remove any creases and pockets

Position embrace® over the injection/scarred area so that the Applicator is parallel to the length of the area and faces away from your skin.

PRESS AND HOLD embrace® against the skin for 60 seconds. Make sure to press firmly on the edges and corners.

STEP 2: Release

Use one hand to hold embrace® in place. Use the other hand to press firmly across the entire surface area of the Applicator to ensure the patch is adhered well to the skin.

Holding embrace® against your skin with one hand, use your other hand to pull one Release Tab to the side along with the edge of the Applicator.

Repeat this step with the other Release Tab. The Applicator will completely detach, leaving the patch adhered to the skin.

Smooth out any uneven areas, flatten any air pockets, and secure and raised corners or edges.

Example for 7 Day CGM Site Rotation with embrace small

Week 1

Insert CGM in area of choice. Wear 7 days and then rotate to next area

Week 2

After removing, immediately apply embrace over injured site to PROTECT from scarring. Wear 7 days while wearing CGM in next area

Week 3

Rotate CGM to new area and repeat treatment with embrace at previously used site

Week 4

Repeat rotation pattern with each new area used

Example for 14 Day CGM Site Rotation with embrace small

Week 1 & 2

Insert CGM in area of choice. Wear 14 days and then rotate to next area

Week 3 & 4

After removing, immediately apply embrace over injured site to PROTECT from scarring. Wear 10-14 days while wearing CGM in next area. Repeat rotation pattern with each new area used

Frid, A. H., Hirsch, L. J., Menchior, A. R., Morel, D. R. & Strauss, K. W. Worldwide Injection Technique Questionnaire Study: Injecting Complications and the Role of the Professional. Mayo Clin Proc 91, 1224-30, doi:10.1016/j.mayocp.2016.06.012 (2016).

Blanco, M., Hernández, M. T., Strauss, K. W., Amaya, M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metab. 2013 Oct; 39(5) 445–53. doi:10.1016/j.diabet.2013.05.006. Epub 2013 Jul 22. PMID: 23886784.

Frid, A. H., Kreugel G., Grassi G., et.al. New insulin delivery recommendations. Mayo Clin Proc 2016-91(9) 1231-55

We're here to support your use of embrace® to make sure you experience the best possible results. Contact us for questions or additional information.

1-855-722-7879
Mon-Fri 8AM-4:30PM EST
support@neodynebio.com
www.EmbraceDiabetesCare.com

EMBRACE is a registered trademark of Neodyne Biosciences, Inc. All other trademarks are the property of their respective owners. © Neodyne Biosciences, Inc. All Rights Reserved.

Download

stack of papers Tips for Patients Injecting Daily

Experts agree with the following steps*:

  • Choose a part of the body
  • Divide into 4 areas
  • Use one area every 7-10 days depending on your CGM
  • Always use a new site
  • Avoid using a single site more than once every 4 weeks
  • Follow your health care professional's recommendations for site rotation

Use for diabetes-related injection-induced scarring

Scarring from on-going use of wearables can significantly impact glycemic control

  • GREATER glycemic variability - up to 7 times higher*
  • INCREASED use of insulin - up to 35% more†
  • HIGHER A1c level - up to 0.55 higher*
diagram of device with parts labeled

STEP 1: Apply

Holding embrace® on its outer edges, use the Peel Tabs to peel off the clear protective liner that covers the adhesive patch.

DO NOT touch the adhesive patch with your fingers.

Gently bow the Applicator with both hands to remove any creases and pockets

Position embrace® over the injection/scarred area so that the Applicator is parallel to the length of the area and faces away from your skin.

PRESS AND HOLD embrace® against the skin for 60 seconds. Make sure to press firmly on the edges and corners.

STEP 2: Release

Use one hand to hold embrace® in place. Use the other hand to press firmly across the entire surface area of the Applicator to ensure the patch is adhered well to the skin.

Holding embrace® against your skin with one hand, use your other hand to pull one Release Tab to the side along with the edge of the Applicator.

Repeat this step with the other Release Tab. The Applicator will completely detach, leaving the patch adhered to the skin.

Smooth out any uneven areas, flatten any air pockets, and secure and raised corners or edges.

Example for site rotation while injecting daily using embrace large

Day 1 - 10

Inject per your physician's recommendations in area of choice

Day 11

Immediately apply embrace over injured injection site to PROTECT from scarring. Wear 10 days while injecting new area

Day 22

Repeat treatment with embrace at previously used site and rotate injections to next area

Day 33

Continue rotation pattern with each new area used

Frid, A. H., Hirsch, L. J., Menchior, A. R., Morel, D. R. & Strauss, K. W. Worldwide Injection Technique Questionnaire Study: Injecting Complications and the Role of the Professional. Mayo Clin Proc 91, 1224-30, doi:10.1016/j.mayocp.2016.06.012 (2016).

Blanco, M., Hernández, M. T., Strauss, K. W., Amaya, M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metab. 2013 Oct; 39(5) 445–53. doi:10.1016/j.diabet.2013.05.006. Epub 2013 Jul 22. PMID: 23886784.

Frid, A. H., Kreugel G., Grassi G., et.al. New insulin delivery recommendations. Mayo Clin Proc 2016-91(9) 1231-55

We're here to support your use of embrace® to make sure you experience the best possible results. Contact us for questions or additional information.

1-855-722-7879
Mon-Fri 8AM-4:30PM EST
support@neodynebio.com
www.EmbraceDiabetesCare.com

EMBRACE is a registered trademark of Neodyne Biosciences, Inc. All other trademarks are the property of their respective owners. © Neodyne Biosciences, Inc. All Rights Reserved.

Download

stack of papers Tips for Patients Using Insulin Pumps

Experts agree with the following steps*:

  • Choose a part of the body
  • Divide into 4 areas
  • Use one area every 7-10 days depending on your pump set type
  • Always use a new site
  • Avoid using a single site more than once every 4 weeks
  • Follow your health care professional's recommendations for site rotation

Use for diabetes-related injection-induced scarring

Scarring from on-going use of wearables can significantly impact glycemic control

  • GREATER glycemic variability - up to 7 times higher*
  • INCREASED use of insulin - up to 35% more†
  • HIGHER A1c level - up to 0.55 higher*
diagram of device with parts labeled

STEP 1: Apply

Holding embrace® on its outer edges, use the Peel Tabs to peel off the clear protective liner that covers the adhesive patch.

DO NOT touch the adhesive patch with your fingers.

Gently bow the Applicator with both hands to remove any creases and pockets

Position embrace® over the injection/scarred area so that the Applicator is parallel to the length of the area and faces away from your skin.

PRESS AND HOLD embrace® against the skin for 60 seconds. Make sure to press firmly on the edges and corners.

STEP 2: Release

Use one hand to hold embrace® in place. Use the other hand to press firmly across the entire surface area of the Applicator to ensure the patch is adhered well to the skin.

Holding embrace® against your skin with one hand, use your other hand to pull one Release Tab to the side along with the edge of the Applicator.

Repeat this step with the other Release Tab. The Applicator will completely detach, leaving the patch adhered to the skin.

Smooth out any uneven areas, flatten any air pockets, and secure and raised corners or edges.

Example for Omnipod site rotation with embrace medium

Day 1 - 9

Area = 3 pod sites
Insert 3 pods aligned in area of choice

Day 10

After removing the third pod, immediately apply embrace over injured sited to PROTECT from scarring. Wear 9 days while pumping in next area

Day 19

Rotate pods to a new area and repeat treatment with embrace at previously used site

Day 28

Continue rotation pattern with each new area used

Example for 3 Day pump infusion set site rotation with embrace medium

Day 1

Area = 3 pod sites
Insert 3 pods aligned in area of choice

Day 10

After removing third pod, immediately apply embrace over injured sites to PROTECT from scarring. Wear 9 days while pumping in next area

Day 20

Rotate pods to new area and repeat treatment with embrace at previously used site

Day 30

Continue rotation pattern with each new area used

Example for 7 Day pump infusion set site rotation with embrace small

Week 1

Insert pumpset in area of choice

Week 2

After removing, immediately apply embrace over injured site to PROTECT from scarring. Wear 7 days while pumping in next area

Week 3

Rotate pumpset to new area and repeat treatment with embrace at previously used site

Week 4

Continue rotation pattern with each new area used

Frid, A. H., Hirsch, L. J., Menchior, A. R., Morel, D. R. & Strauss, K. W. Worldwide Injection Technique Questionnaire Study: Injecting Complications and the Role of the Professional. Mayo Clin Proc 91, 1224-30, doi:10.1016/j.mayocp.2016.06.012 (2016).

Blanco, M., Hernández, M. T., Strauss, K. W., Amaya, M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metab. 2013 Oct; 39(5) 445–53. doi:10.1016/j.diabet.2013.05.006. Epub 2013 Jul 22. PMID: 23886784.

Frid, A. H., Kreugel G., Grassi G., et.al. New insulin delivery recommendations. Mayo Clin Proc 2016-91(9) 1231-55

We're here to support your use of embrace® to make sure you experience the best possible results. Contact us for questions or additional information.

1-855-722-7879
Mon-Fri 8AM-4:30PM EST
support@neodynebio.com
www.EmbraceDiabetesCare.com

EMBRACE is a registered trademark of Neodyne Biosciences, Inc. All other trademarks are the property of their respective owners. © Neodyne Biosciences, Inc. All Rights Reserved.

Protect Your Sites With embrace®

★★★★★
"I am excited for the possiblity of embrace to use for prevention of LH because until now the only treatment for LH was to rotate their insulin sites!"
NB
Nancy Bristow
RN, CDCES
★★★★★
"embrace will change the treatement of lipohypertrophy like continuous glucose monitoring changed how people with diabetes check their blood sugar"
DM
David K Miller
RN, BSN, MS Ed, CDCES, LDE
★★★★★
"Being able to provide a simple patch solution to resolve fibrotic scarring versus multiple topical applications a day is an easy decision to make"
CD
Christina DiLoreto
RD, LD, CDCES